MMRC Horizon One: A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma (MMRC-099)
Summary
MMRC Horizon One is a Phase 2 adaptive platform trial designed to evaluate multiple novel therapies for patients with relapsed or refractory multiple myeloma. The trial uses a Master Protocol structure that allows new investigational treatment arms to be added over time as they become trial-ready. This design aims to efficiently compare different treatments and match patients to optimal therapies. As a newly registered trial, no efficacy or safety results are yet available.
Plain Language Summary
Scientists have set up a new type of clinical trial to test several different treatments for multiple myeloma that has come back or stopped responding to previous treatments. The trial is designed to be flexible, allowing new treatments to be added as they become available for testing. This approach could help researchers find better treatments faster, but the trial is just getting started and there are no results yet.
Key Implications
- This trial infrastructure may accelerate the evaluation of multiple myeloma treatments by testing several drugs within one coordinated framework, though actual benefits will depend on the specific therapies evaluated
- Patients with relapsed or refractory multiple myeloma may have access to investigational treatments through this trial, assuming they meet eligibility criteria and a trial site is accessible
- The adaptive design could provide faster answers about which treatments work best for specific patient subgroups, though this remains to be demonstrated as the trial progresses
Patient Relevance
Who This Affects
Patients with multiple myeloma that has returned after previous treatment or has stopped responding to current therapies